{"id":"generic-zoledronic-acid","safety":{"commonSideEffects":[{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Atypical femoral fractures"},{"rate":null,"effect":"Renal impairment"},{"rate":"20-30","effect":"Fever"},{"rate":"10-20","effect":"Myalgia/arthralgia"},{"rate":"10-15","effect":"Nausea"}]},"_chembl":null,"_fixedAt":"2026-03-30T15:56:37.199932","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a bisphosphonate, zoledronic acid binds to hydroxyapatite in bone and is taken up by osteoclasts during bone resorption. It inhibits farnesyl pyrophosphate synthase, disrupting the prenylation of small GTPases required for osteoclast function and survival, leading to decreased bone turnover and increased bone mineral density.","oneSentence":"Zoledronic acid inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:11.643Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic bone disease in cancer patients"},{"name":"Multiple myeloma with bone involvement"},{"name":"Osteoporosis"},{"name":"Paget's disease of bone"},{"name":"Hypercalcemia of malignancy"}]},"_fixedFields":["pubmed(874)"],"trialDetails":[{"nctId":"NCT02520362","phase":"","title":"Denosumab Safety Assessment in Multiple Observational Databases","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-31","conditions":"Osteoporosis","enrollment":517991},{"nctId":"NCT03158246","phase":"PHASE4","title":"Generic Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women","status":"UNKNOWN","sponsor":"Cttq","startDate":"2017-06-01","conditions":"Osteoporosis, Postmenopausal","enrollment":466}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":874,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Yigu"],"phase":"marketed","status":"active","brandName":"Generic Zoledronic Acid","genericName":"Generic Zoledronic Acid","companyName":"Cttq","companyId":"cttq","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zoledronic acid inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Used for Metastatic bone disease in cancer patients, Multiple myeloma with bone involvement, Osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}